Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Lilly partners with Amazon to deliver Zepbound and other drugs

Published 03/13/2024, 06:06 AM
Updated 03/13/2024, 06:10 AM
© Reuters. FILE PHOTO: Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo

By Patrick Wingrove

(Reuters) - Eli Lilly (NYSE:LLY) said on Wednesday it has brought on Amazon.com (NASDAQ:AMZN)'s pharmacy unit to deliver drug prescriptions sent to its direct-to-consumer service, LillyDirect.

Lilly launched the platform in January to enable patients to obtain their migraine, diabetes and obesity drugs, including the popular weight-loss medicine Zepbound, directly from the company via delivery from online pharmacy Truepill.

The drugmaker said prescriptions sent to LillyDirect Pharmacy Solutions would now be delivered by either Amazon Pharmacy or Truepill, depending on the patient’s insurance coverage and other factors.

Lilly's vice president of managed healthcare services, Frank Cunningham, said they planned to split the orders between the two companies. He said Lilly was "very pleased" with the number of prescriptions it had filled through LillyDirect but declined to share the number.

A Lilly spokesperson said in an emailed statement that the website has generated significant interest since the launch and that the drugmaker "looked forward to continuing to enhance LillyDirect with additional medicines, partners and service providers in the near future."

Cunningham said the Indianapolis-based drugmaker was considering partnering with a retail pharmacy to offer a pick-up option for LillyDirect customers.

Walgreens CEO Tim Wentworth told Reuters shortly after LillyDirect was launched that the pharmacy chain could be "a very natural potential partner for someone like Lilly."

LillyDirect was launched on the back of surging demand last year for powerful weight-loss drugs including Zepbound and Novo Nordisk (NYSE:NVO)'s Wegovy.

The market for obesity drugs is estimated to reach at least $100 billion by the end of the decade, as consumers flock to the new treatments that have been shown to reduce weight by as much as 20%.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Lilly CEO David Ricks told Reuters in January that the website would ensure that coupons that bring the cost of Zepbound down to $550 a month were applied, and would also encourage users to avoid compounded or fake versions of the medicine.

The website also connects patients to independent telehealth providers who can complement their current team of doctors or be an alternative to in-person care for certain conditions, the company has previously said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.